Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
2009-11-19

BPV Entry and Trafficking in EBTr Cells
Enkhmart Dudleenamjil
Brigham Young University - Provo

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Microbiology Commons

BYU ScholarsArchive Citation
Dudleenamjil, Enkhmart, "BPV Entry and Trafficking in EBTr Cells" (2009). Theses and Dissertations. 2301.
https://scholarsarchive.byu.edu/etd/2301

This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more
information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.

BOVINE PARVOVIRUS ENTRY AND TRAFFICKING
IN EBTr CELLS

by

Enkhmart Dudleenamjil

A dissertation submitted to the faculty of
Brigham Young University
In partial fulfillment of the requirements for the degree of

Doctor of Philosophy

Department of Microbiology and Molecular Biology
Brigham Young University
December 2009

BRIGHAM YOUNG UNIVERSITY

GRADUATE COMMITTEE APPROVAL

Of a dissertation submitted by
Enkhmart Dudleenamjil

This dissertation has been read by each member of the following graduate committee
and by majority vote has been found to be satisfactory.

_____________________________
Date

_____________________________________
F. Brent Johnson, Chair

_____________________________
Date

_____________________________________
Byron K. Murray

_____________________________
Date

_____________________________________
Richard A. Robison

_____________________________
Date

_____________________________________
Brent L. Nielsen

_____________________________
Date

_____________________________________
Scott D.Grimshaw

ii

BRIGHAM YOUNG UNIVERSITY

As chair of the candidate’s graduate committee, I have read the dissertation of
Enkhmart Dudleenamjil in its final form and have found that (1) its format, citations, and
bibliographical style are consistent and acceptable and fulfill university and department
style requirements; (2) its illustrative materials including figures, tables, and charts are
in place; and (3) the final manuscript is satisfactory to the graduate committee and is
ready for submission to the university library.

_________________________
Date

_____________________________________
F. Brent Johnson
Chair, Graduate Committee

Accepted for the Department
_____________________________________
Richard A. Robison
Graduate coordinator

Accepted for the College
_____________________________________
Rodney J. Brown
Dean, College of Life Sciences

iii

ABSTRACT
BOVINE PARVOVIRUS ENTRY AND TRAFFICKING
IN EBTr CELLS
Enkhmart Dudleenamjil

Department of Microbiology and Molecular Biology
Doctor of Philosophy
Bovine Parvovirus (BPV) belongs to the genus Bocavirus, family Parvoviridae. BPV is the
leading etiologic agent among the pathogens that cause primary gastroenteritis of cattle. Many
of the intracellular events associated with virus replication are unknown. In this research project,
we investigated BPV internalization into the host cell and trafficking in the cytosol. Preliminarily,
EBTr cells had abundant clathrin, virus attached to purified clathrin, and EM micrographs
revealed virus in endocytic vacuoles. Assays detecting virus infectivity (i.e. viral protein
synthesis), virus production (completion of the replication cycle), and quantitative PCR (qPCR)
to detect viral transcripts were used to evaluate virus uptake and subsequent trafficking events
in the presence of selective inhibitors. Cell toxicity mediated by the drugs was evaluated by the
MTT test. Virucidal effects of the drugs were assessed. A control virus was used to verify the
inhibitor technology. Immunofluoresceinated virus particles were found in clathrin-rich early
endosomes. Clathrin-mediated endocytosis (CME) was examined by clathrin polymerization
inhibiting agent (chloropromazine), lysosomotropic agents (ammonium chloride and
chloroquine), a vacuolar ATPase inhibitor (bafilomycin A1), and a blocker of transition between
endosomes (brefeldin A). Caveosome pathway inhibitors included phorbol 12-myristate 13acetate (a suppressor of caveolae formation), nystatin and methyl-beta-cyclodextrin (lipid raft
blockers), and genistein (a tyrosine kinase phosphorylation inhibitor). Trafficking of BPV was
investigated using specific inhibitors of proteasomal activity, actin-myosin function, and
microtubule-dynein function. The proteasomal protease suppressor (lactacystin), and a
proteasomal chymotrypsin inhibitor (epoxomicin) were used. The role of actin was probed by
cytochlasin D, latrunculin A, and ML-7. The microtubule inhibitors nocodazole, vanadate, and
EHNA were used to probe microtubule function. The inhibitors of CME reduced virus production
and reduced infectivity, a result confirmed by qPCR. The blockers of caveolin-mediated entry
did not interfere with virus production nor virus infectivity. Proteasome activity blockage did not
affect the virus replication. But the virus cycle was affected by actin blockage and by
microtubule blockage detected by qPCR. Taken together these data indicate that BPV uptake is
mediated by clathrin coated pits and is acid-dependent. Further processing of BPV in the
cytosol does not require proteasomal enzymes. Actin-associated vesicular transport appears to
be essential to virus replication and trafficking to the nucleus appears to be mediated by
microtubules.
Key Words: Bovine parvovirus, clathrin mediated endocytosis, virus trafficking, proteasomes,
actin, microtubules, qPCR
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INTRODUCTION

The Parvovirus family (Parvoviridae) has expanded over recent years as new
isolates have been identified as small single stranded DNA viruses that infect either
vertebrate or nonvertebrate hosts. Members of the family have been recognized as
unique, simple viruses containing two to three open reading frames with one to three
promoters. The proteins, as final gene products, are produced by a combination of
post-transcriptional splicing and leaky scanning for initiation of protein synthesis. Thus,
these viruses present a variety of interesting molecular mechanisms involved in gene
expression. Moreover, many of these viruses are important pathogens of humans or
animals that invariably target mitotic cells. Further, the adeno-associated viruses in this
group have a long history of use as experimental gene vectors for human gene therapy
of inherited genetic disorders. (TABLE 1. Classification of the Parvoviridae family).
Bocaviruses
Bovine parvovirus (BPV) is a member of the genus Bocavirus, family
Parvoviridae along with canine minute virus (CnMV) and human bocavirus (HBoV). BPV
is a small (22 nm), non-enveloped, icosahedral virus. BPV is a pathogen of cattle found
worldwide (28) that causes severe gastroenteritis in calves, mild respiratory infection,
and may cause reproductive failure (2, 77). Infections often result in a viremic phase.
Therefore, this virus is a contamination risk for commercially prepared bovine serum
and bovine products. BPV has often been used as a model for studies on viruses that
are now classified as bocaviruses. The genome consists of single stranded DNA
(ssDNA) that is composed of about 5515 nucleotides (19, 20, 103, 113, 122). The
genome contains non-identical palindromic sequences at the two ends (20). The
1

palindromic sequences have cis signals that are important for genome replication (9, 20,
110). The negative ssDNA strand is the predominately encapsidated form although a
minor proportion of virions contain plus strands. The genome has three open reading
frames (ORFs): the left ORF encodes the nonstructural proteins NS1 and NS2; the
central ORF encodes the nonstructural protein NP1; and the right ORF encodes three
structural proteins VP1, VP2, and VP3 (19, 68,103). The virus does not encode
polymerases. BPV genome replication relies on host cell DNA polymerase and
replication factors found in S-phase cells (9, 20), and transcription is carried out by cell
RNA polymerase II (9, 20). Intriguingly, the genomic organization of HBoV, the second
human-pathogenic parvovirus known (discovered after parvovirus B19), closely
resembles the other known bocaviruses BPV and CnMV (2, 10, 63, 75, 122). The midORF product of HBoV is homologous to NP1 of BPV and CnMV, and these proteins
have 47% amino acid identity. The proteins of the two major ORFs of HBoV have 4243% homology with NS1, VP1, and VP2 proteins of BPV and CnMV (2, 10). It has been
reported that HBoV is one of the most common viruses in respiratory secretions of ill
patients, and the virus has recently been detected in blood and fecal samples.
Concerning BPV replication and virus-cell interactions, Thacker and Johnson
(124) identified the BPV hemagglutination receptor on erythrocytes as glycophorin A
(GPA), and Blackburn et al. (11) showed BPV binding to α-2,3-linked sialic acid located
on the O-linked oligosaccharides of the GPA molecule. Moreover, BPV attachment
occurs on both α-2,3-O-linked and α-2,3-N-linked sialic acids on nucleated bovine host
cells (61). However, the processes of viral penetration into the cell and trafficking in the
cytoplasm to the nuclear compartment have not been well defined beyond receptor
binding.
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Viral entry into the host cell includes the transport of the viral genome across the
cytoplasmic membrane and subsequent release of the genome into the cytosol and, for
DNA viruses such as BPV, subsequent trafficking to the nucleus. Nonenveloped viruses
like BPV often exploit receptor-mediated endocytosis to deliver their genomes into the
cytoplasm (56, 78, 98, 102). Enveloped viruses that utilize acid-mediated endocytosis
generally undergo membrane fusion events that allow for pore formation between the
viral envelope and the vacuolar membrane releasing the viral nucleocapsid into the cell
cytoplasm where viral replication ensues. Some enveloped viruses fuse with the
cytoplasmic membrane directly avoiding the necessity of vacuolar uptake.
TABLE 1. Classification of the Parvoviridae familya
Family
Subfamily
Genus
Type species
Parvoviridae
Parvovirinae
Parvovirus
Minute Virus of Mice
Erythrovirus
Human parvovirus B19
Dependovirus
Adeno-associated virus type
2
Amdovirus
Aleutian mink disease virus
Bocavirus
Bovine parvovirus
Densovirinae
Densovirus
Junonia coenia densovirus
Iteravirus
Bombyx mori densovirus
Brevidensovirus Aedes aegypti densovirus
Pefundensovirus Periplaneta fuliginosa
densovirus
a
Modified after C.M. Fauquet et al., Virus Taxonomy: Eighth Report of the
International Committee on Taxonomy of Viruses. 2005. Elsevier Academic Press,
San Diego CA

Endocytosis. Several possible pathways of receptor-mediated endocytosis are
recognized: clathrin- and caveolin-mediated endocytosis, macropinocytosis, and novel
nonclathrin/noncaveolin pathways (16, 27, 31, 64, 78, 81, 82, 84, 98, 99, 112, 119). To
date, for viral infections that have been studied, viruses mostly take advantage of
clathrin-associated endocytosis for their internalization (78, 98, 112). During clathrindependent endocytosis, transport vesicles are surrounded by a clathrin coat, which is a
3

three-dimensional array of triskelia. A triskelion is composed of three clathrin heavy
chains (CHCs) (approximately 190-kDa) and three light chains (CLCs) (25-29 kDa), and
has three-fold rotational symmetry (40, 85). Ligands that are to be transported to the
cytosol are concentrated on the cell surface, and the concentrated ligands as a patch
trigger recruitment of clathrin-adaptor proteins to the cytoplasmic side of the plasma
membrane. Clathrin-adaptor complexes (APs) include the main distinct complexes, AP1
and AP2, and the third protein, AP180. APs bind to membranes by recognizing
phosphoinositides and link clathrin to the membrane. Therefore, clathrin coated vesicles
are three-layered: the internalized membrane layer with its embedded receptor/ligand
complex, a middle layer that is composed of APs, and the fibrous clathrin coat (40).
Clathrin coated vesicles (CCVs) are one of the most common and well defined coated
or transport vesicles. These vesicles are classified according to the major components
of the protein coat that surrounds them during their formation and early life. CCVs are
so-called because the major component of the coat is clathrin, and membrane
trafficking through CCVs is named CME. Once fission of the pit has occurred through
the action of accessory proteins including dynamin and other proteins forming CCVs,
the clathrin coat must be rapidly shed to allow fusion of the vesicle with its target
membrane. Uncoating of clathrin is resolved by auxilin and the molecular chaperone
Hsc70 (heat shock protein 70). Auxilin interacts with assembled clathrin and binds to
Hsc70 via its carboxyl-terminal J domain triggering Hsc70’s ATPase activity. Hsc 70
then cleaves clathrin-clathrin interactions, causing shedding of the clathrin coat.
Disassembled clathrin and accessory proteins are recycled and promote the CCV cycle
(15, 29, 30, 35, 40, 52, 55, 69, 73, 79, 102, 121). The cargo-containing vesicle then
matures to the early endosome containing a mildly acidic environment (pH 6.5 to 6.0).
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Virus engaged receptors are uncoupled from their ligands at this mildly acidic
environment of the early endosomes, and receptor molecules are recycled back to the
plasma membrane (126). The early endosomes are major sorting stations where
endocytosed cargo can be released to the cytoplasm or can progress to more acidic
late endosomes (pH 6.0 to 5.5), and the acidification of endosomes is required for
release of uptaken virus into the cytoplasm (26, 45, 66, 78, 98, 108, 112, 115,126). The
genome or nucleocapsids of viruses are released into the cytosol by fusion of the viral
envelope with the endosomal membrane for enveloped viruses or, for non-enveloped
viruses, capsid disassembly occurs in the endosome with subsequent genomic escape
to the cytosol (14,118). The acidic pH of endosomes plays an essential role to trigger
these events. Further, some non-enveloped viruses begin the uncoating process in the
late endosome, but complete uncoating is delayed, and it is a nuclear event. For
example, in some instances such as adenovirus and canine parvovirus infections, the
genome together with modified capsid components translocate to the nuclear
membrane (14, 57,129) where final uncoating occurs. Viruses that exploit clathrindependent, acid-mediated entry are sensitive to the inhibitors of endosomal
acidification. Thus, inhibition of virus replication by endosomal pH inhibitors is taken as
evidence for virus tracking through an acid-mediated endocytic pathway.
In contrast to clathrin-mediated pH-dependent endocytosis, caveolin-mediated
entry is a triggered event (37, 54, 96, 112). Binding of virus particles to a receptor
molecule on the cell surface induces the clustering of lipid rafts with a high content of
cholesterol and sphingolipids. The area of the plasma membrane with the clusters
invaginate to the cytosol, and the invaginate is surrounded by caveolins, the most
characterized proteins of caveolae-mediated entry. These caveolin coated invaginates
5

formed at the cholesterol-rich microdomains at the plasma membrane are named
caveolae. Caveolins stabilize caveolae, and they are remarkably static in caveosomes
(78, 97). Accessory proteins involved in caveolae-mediated entry are dynamin and
actin, and they are recruited by tyrosine kinase activites (31, 78, 96, 98, 100, 115). The
caveolae invaginates containing the virus/receptor complex, closes, pinches off from the
cell membrane, and fuses together forming caveosomes. Caveosomes are certainly
part of the endocytic organelles with a neutral pH and the absence of markers for early,
recycling, and late endosomes (96, 98). Caveosomes connect with the smooth
endoplasmic reticulum (ER), early and late endosomes, and the cell membrane.
Release of virus uptaken by the caveolar/raft system can occur in caveosomes (Echo
1), the ER (SV40), and endosomes (polyomaviruses and BK virus) (39, 78, 98). The
interaction with endosomes may be crucial for some viruses that are uptaken by
caveolae-mediated endocytosis but requires a low-pH environment for escape to the
cytoplasm. Pharmacological/chemical inhibitors, targeted for a certain part of
interconnected organelles of caveolae entry, are extensively exploited to examine a role
of caveolae pathways for virus entry with defined cell entry routes.
Cell entry routes of some members of the Parvoviridae family have been
described. Parvoviruses are known to utilize a variety of cell surface molecules as their
receptor including glycoproteins, glycolipids, and glycans (10, 11, 12, 24, 92, 124). It
has been reported that parvoviruses with known cell entry routes are up-taken into
clathrin-associated endosomes and establish successful infections (4, 24, 51, 91, 93,
106, 128). Adeno-associated virus (AAV)’s entry into the host cell is mediated by
clathrin coated pits and then routes to the late endosomes (3). The virus particles then
escape to the cytoplasm where they are partially degraded by the proteasome and
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delivered to the nucleus for replication (34). AAV’s trafficking to the nucleus appears to
be independent from the microtubule network (53). The canine parvovirus uses the
transferrin receptor for attachment (92), enters through the clathrin coated pits, and
localizes in endosomes (56, 93, 129). Minute virus of mice (MVM)’s cell entry and
following events in the cytoplasm were investigated analyzing the effects of drugs that
interfere with the endosomal acidification and ubiquitin-proteasome activities. Results
suggested that MVM’s entry is pH-dependent, and the interaction with the ubiquitinproteasome system is required for MVM replication (106). The relatively rapid endocytic
uptake of parvoviruses appears to be followed by slower traffic along the endocytic
compartments toward the nucleus. The endosomal pathway undertaken by
parvoviruses appears to be complex and depends on the virus, its concentration, and
likely the cell type (33, 76, 117, 120, 132). Conformational alterations in capsid
structure probably occur in the endosomal compartment facilitating uncoating and
transport to the nucleus. However, the place where the virus particles escape remains
unclear (128). As the virus ultimately reaches the nucleus, some evidence suggests
that parvovirus nuclear entry might occur independently of the nuclear pore complex
(23). Once inside the nucleus and uncoated, parvoviruses’ replication depends on the
cell S-phase DNA replicative machinery and transcriptional enzymes and factors.
Inhibitors of endocytosis and cell trafficking. As noted above, blocking the entrance
pathway with chemical inhibitors with known sites of action can provide information on
the specific route viruses exploit for cell entry. This strategy has become a commonly
used technique to elucidate viral entry pathways. Following are descriptions of the
inhibitors used in the current study and their modes of action.
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Chlorpromazine (CHPZ). The interaction of amphipathic CHZP with the plasma
membrane lipid bilayer increases lipid fluidity within the plasma membrane. This
physical state of the plasma membrane lipids disrupts the formation of large membrane
invaginations such as clathrin coated pits. This pharmacological effect eventually breaks
clathrin recycling between the plasma membrane and cell organelles including
endosomes. Overall, interruption of clathrin recycling, and depletion of functional
clathrin coated pits at the cell membrane suppress CME (13, 16, 57, 74, 102, 119).
CHPZ treatment blocked cell entry of west nile virus (WNV), mouse hepatitis virus type2
(MHV-2), hepatitis C virus (HCV), equine infectious anemia virus (EIAV), severe acute
respiratory syndrome coronavirus (SARS-CoV), feline calicivirus (FCV), mouse
polyomavirus (PyV), baculovirus, bovine viral diarrhea virus (BVDV), foot-and-mouth
disease virus (FMDV), rubella virus (RV), hantaan virus (HTV), and
densonucleosisviruses (DNV). The authors conclude these viruses are taken up by
clathrin-mediated, pH-dependent endocytosis taking together results they found (13, 15,
16, 21, 43, 57, 59, 60, 64, 67, 71, 74, 90, 102, 119, 128).
Ammonium chloride (NH4Cl). The acidification of endocytic vesicles triggers a
conformational change in the viral capsid protein or envelope glycoproteins that leads to
release of viral genome or nucleocapsid into the cytoplasm. NH4Cl and chloroquine
diffuse across the endosomal membrane and become protonated. As a result of this
action, the environment of the endosomal compartment becomes less acidic, and this
neutral environment arrests release of the viral genome or nucleocapsid and hinders
progress of subsequent replication events if the endosomal acidification is required for
early events of virus entry (43, 59, 71). Study groups (35, 52) observed that
neutralization of the acidic environment of endosomal vesicles causes the arrest of the
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pinching off of coated pits from the cell surface. NH4Cl used as a selective inhibitor of
endosomal acidification has been reported in the investigation of PyV, EIAV, BK virus
(BKV), BVDV, DNV, SARS-CoV, and human immunodeficiency virus type 1 (HIV-1) (25,
39, 43, 57, 60, 67, 71, 128). It has been reported that NH4Cl did not affect infections of
amphotropic murine leukemia virus (A-MLV) and hepatitis B virus (HBV) (8, 50).
Chloroquine (CHLO). This organelle acidification blocker has been employed to
examine entry pathways of FCV, EIAV, BKV, simian virus 40 (SV40), BVDV, HBV,
DNV, MVM, MHV-2, WNV, and HIV-1 (21, 25, 43, 50, 60, 67, 76, 89, 102, 106, 119,
128). SV40 and HBV, internalized by pH-independent pathways, were insensitive to the
lysomotropic agent CHLO (50, 89).
Bafilomycin A1(Baf A1). The vacuolar proton ATPase (V-ATPase) is a
multisubunit enzyme complex, and it is responsible for the acidification of membranebounded organelles like endosomes. V-ATPase transports H+ over membranes against
an electrochemical potential under ATP hydrolysis, and H + ions acidify endosomal
environments. Baf A1 blocks the V-ATPase activity causing neutralization of the acidic
environment of endosomes. Baf A1 is routinely used as a selective suppressor of VATPases, and it is used to test whether specific viral entry is reliant on endosomal
acidification (6, 22, 36, 60, 130). Entry pathway studies of PyV, FCV, EIAV, BVDV,
AAV, MVM, MHV-2, poliovirus (PV), baculovirus, HCV, influenza virus, HIV-1, and
human rhinovirus 14 (HRV14) have analyzed the effects of Baf A1 and examined the
role of endosomal acidification in a specific route that leads to replication (5, 13, 14, 33,
43, 49, 59, 67, 74, 76, 102, 106, 111, 119).
Brefeldin A (BFA). BFA interrupts transition of early to late endosomes and
disrupts the Golgi apparatus. But this drug has no effect on early endosomes. BFA was
9

used in our study to test BPV transport from early to late endosomes. The vesicles
containing the virus/receptor complex lose the clathrin coat and mature to the early
endosomes. Some viruses escape to the cytoplasm under the effects of the acidic
environment (6.5 to 6.0) of the early endosome. The early endosome becomes a
transport intermediate recruiting Arf1 dependent coatomer proteins (COPI) (COPI,
clathrin, and AP-1) and converts to the late endosome if virus does not escape from this
station. Arf 1 or small GTPase’s activity is catalyzed by Sec7-type GTP-exchange
factors (GEFs). GEFs are primary targets of BFA. Therefore, tubulation or maturation of
early endosomes are delayed, and virus transition to the late endosome is blocked (14,
88, 119). Studies reported that BFA also affects transport between Golgi and
endoplasmic reticulum with the same mechanism through Arf1. BFA was chosen as a
selective inhibitor of pH-dependent endocytosis to investigate early events of PyV,
SV40, AAV, DNV, MVM, PV, and FCV interaction with the host cell (13, 27, 34, 46, 49,
76, 106, 119, 128).
Phorbol 12-myristate 13-acetate (PMA). Caveolae contain a population of the
protein kinase C (PKC) isoenzyme, which have a high affinity and specificity for
caveolae membranes. PKC is essential to regulate caveolae formation, and the precise
mechanism is under investigation. Studies showed that PKC activators such as PMA
interfere with caveolar endocytosis. PKC activators do not affect ligand clustering in
cholesterol-rich membrane domains. But, PMA inhibition of caveolae formation
markedly suppresses the internalization of lipid raft associated ligands (41, 94, 101,
114). The role of caveolar endocytosis in cell entry of filoviruses (Ebola Zaire virus and
Marburg virus), Newcastle disease virus (NDV), and respiratory syncytial virus (RSV)
has been assessed using PMA treatment (59, 72, 131).
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Nystatin (Nys). This polyene antibiotic inhibits endocytosis associated with lipid
rafts. Nystatin interacts with cholesterol of cholesterol-rich membrane domains creating
large aggregates in the membrane. The aggregates accumulate cholesterol and alter
the structure and function of the cholesterol-rich membrane domain. Nys exposure of
cells causes aberrations of the caveolar shape and dispersion of proteins anchored to
the cytoplasmic domain of receptor molecules, thereby internalization of lipid raft ligands
is inhibited (18, 27, 105, 112). To address the role of cholesterol-rich membrane
domains in entry routes of FCV, lymphocytic choriomeningitis virus (LMCV), Py, SV40,
DNV, HTV, RV, filoviruses, and FMDV, Nys was used as a cholesterol sequestering
agent (27, 41, 43, 46, 59, 64, 90, 105, 128).
Methyl-beta-cyclodextrin (MBCD). This chemical is a cyclic heptasaccharide
containing a hydrophobic core that has a high affinity for cholesterol. The interaction of
MBCD with cholesterol forms soluble inclusion complexes and depletes cholesterol at
the cell membrane. It has been reported that MBCD treatment alters caveolae
morphology and mislocates caveolins. These effects interrupt very early events of
caveolin endocytosis. MBCD, as a suppressor of cholesterol-dependent pathway, has
been employed in cell entry studies of BKV, A-MLV, LMCV, parvovirus, PV, DNV, EIAV,
filoviruses, and SARS-CoV (8, 14, 16, 41, 46, 56, 57, 105, 128).
Genistein (Gen). Caveolar vesicles pinch off from the plasma membrane, fuse
together, and route to caveosomes. Caveosomes are considered intermediate stations
of the ligand/receptor complex that is up-taken by caveolar endocytosis. Gen blocks
caveolae-mediated pathway inhibiting the enzyme, tyrosine kinase, which is involved in
the formation of caveosomes (15, 16, 39, 74, 96). In investigations of arenaviruses,
BKV, SV40, HIV, HTV, EIAV, PV, and baculovirus’ entry routes the effects of Gen were
11

analyzed to assess whether caveolar pathway is a selective route to initiate a
successful infection (14, 16, 27, 59, 67, 74, 127).
Lactacystin (Lac). This natural metabolite from Streptomyces spp. irreversibly
blocks the 26S proteasome linked chymotrypsin-like and trypsin-like activities modifying
the β-subunit of the proteasome (34, 123). Lac treatment has been used to examine
whether the ubiquitin-proteasome system is required to establish a productive infection
of orthopoxvirus, AAV, BKV, MHV, and MVM. Together, data from these studies
suggest that proteasome function is linked to replication of orthopoxvirus, AAV, MHV,
and MVM rearranging the capsid (34, 58, 123, 133).
Epoxomicin (Epox). Naturally, Epox is an antitumor agent. It interferes with the
chymotrypsin-like activity of the ubiquitin-proteasome system covalently binding to the
LMP7, X, MECL1, and Z catalytic subunits of the proteasome. In addition, the trypsinlike and peptidyl-glutamyl peptide hydrolyzing activities of proteasomes are inhibited by
Epox treatment to 100- and 1000-fold slower rates, respectively. The inhibition of the
chymotrypsin-like activity of Epox is more potent than Lac inhibition of the chymotrypsinlike activity (106, 109). Studies on replication events of MVM and vaccinia virus (VACV)
demonstrated that the ubiquitin-proteasome activity enhances a productive replication of
these two viruses while blocking the proteasome with Epox. MVM and VACV’ replication
was reduced in the presence of Epox (106, 109).
Cytochalasin D (Cyt D). After uncoating, the viral genome needs to be
transported to proper sites in the cytosol for replication and expression. Viruses, objects
in a scale of nanometers, are not able freely to diffuse through the crowded cytosol and
efficiently find their proper destination by random movement. Thus, viruses hijack cell
cytoskeletal structures to reach proper sites of replication in the cytosol or the nucleus.
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Virus trafficking associated with actin is commonly assessed using Cyt D and latrunculin
A. Cyt D interrupts actin polymerization by occupying the faster-growing “barbed” ends
of actin filaments. This pharmacological inhibition of actin polymerization was used to
characterize the cell transport system involved in FCV, LMCV, DNV, EIAV, PV, FMDV,
and VACV’s trafficking in the cytosol (14, 16, 21, 43, 72, 105, 119, 128).
Latrunculin A (Lat A). This chemical is one of extensively used substances to
block intracellular transport by actin filaments. Lat A binds to monomeric actin, and this
interaction prevents incorporation of actin monomers to filaments. Intracellular trafficking
of Herpes simplex virus 1 (HSV-1), LCMV, BKV, and SV40 has been studied in the
presence of Lat A as an inhibitor of actin polymerization (27, 38, 42, 105).
1-(5-iodonaphlalene-1-sulfonyl)-1H-hexahydro 1,4-diazapine hydrochloride (ML7). ML-7 is a highly specific inhibitor of myosin light chain kinase (MLCK), and it
selectively suppresses active actin that is involved in intracellular transport. ML-7 blocks
phosphorylation of the myosin light chain (MLC). This selective compound has been
used to elucidate movements of intracellular components and the contraction
physiology of smooth muscle (95, 107).
Nocodazole (Noc). Microtubules, one of three principal components of the
cytoskeleton, determine cell shape and mediate a variety of cell movements including
the intracellular transport of organelles. Like actin filaments, microtubules are dynamic
structures that undergo continual assembly and disassembly within the cell. Tubulin, a
heterodimer, consists of α- and β-tubulins and polymerizes to form microtubules. The
microtubule-active drug, Noc, binds to tubulin and then delays the polymerization of the
heterodimers. In this way, Noc interrupts microtubule associated transport in the
cytoplasm (15, 64, 98, 119, 125, 128). Noc was used to study functions of microtubules
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in FCV, SV40, DNV, HBV, RV, PV, and FMDV’s trafficking in the cytosol (14, 21, 27, 62,
64, 128).
Vanadate (Van). Dynein, a motor protein, transports various cellular cargo
including virus/receptor complexes by “walking” along microtubules towards the cell
center, which is the nucleus. DNA viruses, excluding poxviruses, amplify their genome
and transcribe mRNAs in the nucleus. Van disrupts the dynein motor, which leads to the
inhibition of transport along microtubules. This microtubule-active drug has been used in
studies of the intracellular trafficking of HSV as a selective inhibitor of this microtubulebased motor protein (7, 32, 65).
Erythro-9-3(2-hydroxynonyl) adenine (EHNA). EHNA is an inhibitor of dynein
adenosine triphosphatase (ATPase). Analyzing the effects of EHNA allows examination
of the efficiency of the microtubule-based dynein motor on intracellular transport. It has
been reported that EHNA has been utilized in studies of intracellular trafficking of HTV,
BK, and herpers viruses (7, 65, 87, 104).
Studies concerning BPV interactions with its target cell and steps beyond
receptor binding are crucial in elucidating pathogenesis of human parvoviruses and
molecular and cellular mechanisms of bocavirus replication. In this paper, we report
post-binding events of BPV entry into EBTr cells and subsequent trafficking routes. We
confirm the functional importance of the pH sensitive CME in BPV penetration into EBTr
cells and show trafficking associated with actin filaments and microtubules in the
cytosol.
MATERIALS AND METHODS
Virus, cells, and media. The BPV strain used in this study was the original HADEN
isolate obtained from F. R. Abinanti (1). Virus stocks were prepared from infected EBTr
14

(embryonic bovine tracheal) cells, titers were determined as infected focus-forming
units, and stocks were stored frozen at -80oC. EBTr cells, a diploid cell strain (ATCC
NBL-4), were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich)
containing 0.11 % sodium bicarbonate, 10 mM HEPES buffer, 50 μg gentamicin per ml,
and either 5% cosmic calf serum (Hyclone) or 1% Fetal Clone III serum (Hyclone). In
assays where virus infection was measured, Fetal Clone was used in the medium as
cosmic calf serum contains anti-BPV antibodies. BEK (bovine embryonic kidney) cells
and BT (bovine turbinate) cells were used for immunofluorescent studies and virus
stock production, respectively.
Detection of clathrin distribution in EBTr cells. EBTr cells grown on 12 mm glass
coverslips in shell vials were incubated until they reached 80% of confluency. The cells
were fixed in cold acetone then stained by anti-clathrin antibody (mouse IgM anti-human
clathrin MAB, Chemicon, CBL 188) followed by the secondary antibody (goat antimouse IgM, rhodamine-conjugated, Chemicon, AP128R), then observed by
fluorescence microscopy using techniques previously described (61). Images were
collected and stored as digital micrographs.
Virus binding dot-blot assays. Purified glycophorin A (GPA) and purified clathrin
(Sigma-Aldrich) were fixed on nitrocellulose membranes in a dot-blot format. The dotblot procedures were followed as previously described (11, 61). Briefly, the virus
binding substrates GPA and clathrin together with the positive controls, consisting of
BPV antigens purified by ultracentrifugation on CsCl isopycnic gradients and crude
antigens as infected cell lysates, were dotted on the membranes. Negative control dots
consisted of phosphate buffered saline (PBS). Purified virus (20 μl per dot) was added
to the GPA and clathrin wells as well as the control wells and incubated for 30 min at
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room temperature (RT). The membranes were then removed from the dot-blot template
and washed for 30 min in blotto blocker. Following appropriate washes in PBS the
membranes were stained by a protein A-immunoperoxidase complex (IP) followed by
incubation in a solution of 4-Chloronaphthol chromogen and hydrogen peroxide for
visualization of virus attachment to the membrane-fixed molecules as previously
described (124).
Transmission electron microscopy (TEM). At 15 min postinfection cells were fixed in
2% glutaraldehyde-0.06 M cacodylate for 1 h at 4oC and then postfixed for 2 h in
osmium tetraoxide (1:1 dilution with cacodylate) at RT. After dehydration in a grade
series of ethanol solutions, cells were infiltrated in Epon resin. Ultrathin sections (0.1
µm) were mounted on copper grids and stained with uranyl acetate and lead citrate.
Observations were performed with a FEI T12 electron microscope at 80 kV. The virus
particles and infection-associated structures’ images were taken by a Gaton Multiscan
794 digital camera and Image J software.
Pharmacological treatment of EBTr cells during BPV infection. EBTr cells were
treated with pharmacological inhibitors for 30 min prior to the BPV infection at 37oC and
5% CO2. The inhibitors were present for the duration of the infection. A group of
pharmacological agents was used to study whether BPV is up-taken by clathrinmediated, acid-dependent pathway or the caveolae-mediated, acid-independent
pathway. Virus uptake by CME was tested by employing CHPZ, NH4Cl, CHLO, Baf A1,
and BFA. These drugs were purchased from Sigma Aldrich Chemical Company.
Caveolae-mediated entry was investigated by treating the cells with PMA (Fluka
BioChemica), Nys (Sigma Aldrich), MBCD (Sigma Aldrich), and Gen (Sigma Aldrich).
The next group of drugs was used to detect the role of proteosomal enzymes for BPV
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processing in the cytosol. It included Epox and Lac, and they were obtained from Sigma
Aldrich. The third group of drugs consisted of Noc (Sigma Aldrich), Cyt D (Fluka
BioChemica), Lat A (Sigma Aldrich), Van (Sigma Aldrich), EHNA (A. G. Scientific Inc.),
and ML-7 (Alexis Biochemicals). These drugs were used to examine the role of
cytoskeletal structures for BPV trafficking in the cytosol to the nucleus. The
pharmacological agents were stored and dissolved in solvents following manufacturers’
recommendation. The working concentrations of the inhibitors were freshly prepared in
DMEM containing 1% Fetal clone III serum and stored at 4oC. Each drug was prepared
as a set of increasing concentrations based on cell viability/cytotoxicity tests.
Cell viability assay. For all the inhibitors, a dose-response assay was performed to
detect the working doses. Cell viability was assessed by measuring mitochondrial
dehydrogenase activity (the Cytotox-MTT test, Aniara Corp.). Viable cells are able to
reduce MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), and
reduction is measured spectrophotometrically (34). These tests were performed
according to the manufacturer’s instructions. Working concentrations of the selective
inhibitors prepared for BPV entry assays was evaluated for toxicity on EBTr cells.
Concentrations of the pharmacological inhibitors were chosen for further study that did
not exhibit significant toxicity for either virus or cells.
Assessment of possible virucidal effects of the inhibitors. To test for possible direct
virucidal effects of used chemicals, media containing the highest concentrations of
drugs that were tested were inoculated with virus, incubated at RT for 30 min, and then
surviving virus was detected by standard virus assay. Controls included in these tests
were cells infected with BPV stock not pretreated with the drugs.
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Virus infectivity and inhibitor assays. Infectivity assays were designed to test, in the
presence of inhibitor, how many cells would be infected or efficiency of viral protein
synthesis when exposed to a virus stock of known titer. EBTr cells were grown in 24well plates, washed twice with serumless medium to remove any anti-BPV antibody that
was present in the growth medium, and renewed in media supplemented with the
selective inhibitors (see TABLE 2). These cultures were then incubated at 37 oC for 30
min to allow uptake of the chemical inhibitor and the initiation of its biological activity.
The cultures were then infected with virus at three different multiplicities of infection
(MOI) to ensure countable and significantly valid numbers of infected foci. The cultures
were incubated at 37oC for 2 days, the cells fixed with formalin-acetic acid-alcohol (FAA
fixative), and stained for detection of BPV infected cells by IP (61). Dark purple cells
were counted as an indicator of the BPV infected cells. The experiment included mockinfected, drug toxicity controls, cell controls, and virus infectivity controls. The effects of
each drug on BPV infectivity (i.e. protein synthesis) were assessed by three separate
and independent experiments with triplicates of each concentration of the drug. The
replicate experiments showed similar results.

TABLE 2. Chemical inhibitors and their mechanisms of action
Target
Mechanisms of action
Inhibitors of clathrin endocytosis
Chlorpromazine

prevents receptor/ligand induced clathrin
assembly by interfering clathrin recycling.

Chloroquine

raises endosomal pH and blocks clathrin
coated pit formation.

Ammonium chloride

increases endosomal pH and inhibits
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pinching of CCVs from the cell membrane.
Bafilomycin A1

suppresses endosomal acidification by
inhibiting V-ATPase.

Inhibitors of caveolin pathway
Phorbol 12-myristate 13-acetate (PMA) active against caveolae formation delaying
caveolin-1 assembly at microdomains.
Nystatin

dysfunctions caveolae depleting
microdomain cholesterol .

Methyl-beta-cyclodextrin (MBCD)

sequesters microdomain cholesterol at the
plasma membrane.

Genistein

disrupts caveosome formation by blocking
phosphorylation of tyrosine kinase.

Inhibitors of cytosolic trafficking
Early to late endosome transition
suppresses the early-to-late endosomal
Brefeldin A
trafficking by disrupting endosomal
maturation.
Proteasome
Epoxomicin

Lactacystin

Actin
Cytochalasin D

Latrunculin A
ML-7 (1-(5-iodonaphlalene-1-

interferes with the chymotrypsin-like activity
of the ubiquitin-proteasome system.
blocks the 26S proteasome associated
chymotrypsin-like and trypsin-like activities
modifying the β-subunit.

impairs actin polymerization by occupying
the faster-growing “barbed” ends of actin
filament.
prevents incorporation of actin monomers
to filament by binding to monomeric actin.
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sulfonyl)-1H-hexahydro 1,4diazapine hydrochloride)

Microtubule
Nocodazole

Vanadate

specifically blocks intracellular transport via
actin by interfering with phosphorylation of
MLC.

delays microtubule formation by binding to
tubulins.
inhibits transport along microtubules by
disrupting the dynein motor.

EHNA (Erythro-9-3(2-hydroxynonyl) inactivates dynein ATPase that results in
the impairment of microtubule transport.
adenine)

Virus production and inhibitor assays. Production assays tested for the yield of
progeny virions or completion of the replication cycle in experimental infections in the
presence of drug. The virus production assays were carried out as follows. EBTr cell
cultures in 25 cm2 culture flasks at a confluency of 70% to 80% were washed twice with
the serumless medium. The cells were pretreated with the test drug (see TABLE 2) for
30 min at 37oC and then infected with virus at a MOI of 2. The infection was allowed to
proceed for 3 days at 370C in the presence of the drug. The cells were then lysed by
three freeze-thaw cycles and then centrifuged at 1000 rpm for 30 min in a tabletop
centrifuge to remove cell debris. The supernates were tested for virus yields that were
produced in the presence of the drug. The virus titrations were performed as described
above. The cells were fixed with FAA fixative and stained with IP staining for detection
of BPV infected cells. Virus titers were expressed as virus focus-forming units (FFU)
per ml. Values are presented as the averages of triplicate samples. The experiment
included mock-infected, drug toxicity controls, cell controls, and virus infectivity controls.
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The set of the drug concentrations were assessed by separate and independent
experiments with similar results.
Entry of a positive control virus. Adenovirus is internalized by a clathrin-mediated pHdependent pathway (81, 82). Adenovirus entry into HeLa cells was tested by the virus
infectivity assay in order to verify specific inhibition effects of the drugs on BPV entry.
HeLa cells were pretreated with the selective drugs and infected with Adenovirus type 2
for 2 days in the presence of the drugs. The infected cells were fixed with FAA and
stained with IP for visualization of Adenovirus-infected cells. The number of Adenoviruspositive cells in treated cultures was compared to the number of virus positive cells in
inhibitor-negative control cultures.
Fluoresceination of virus. Purified virus was obtained by CsCl isopycnic gradient
ultracentifugation. Cultures of bovine turbinate (BT) cells (Invitrogen) at 70-80%
confluence in 150 cm2 culture flasks were inoculated with BPV stock culture at a MOI of
<0.01 and incubated at 37oC until 4+ cytopathic effect was obtained. Following three
freeze-thaw cycles, the cell debris was removed by low speed centrifugation. The virus
particles, together with small particulate cell structures, were pelleted by
ultracentrifugation for 4 h at 85,000 x g. The pellets were allowed to soak overnight in
pH 8.2 0.01M tris buffer and then suspended by sonication in the tris buffer. Solid CsCl
and CsCl dissolved in tris buffer were combined with the virus to form appropriate
volumes of virus suspensions at a CsCl concentration of 1.4 g/cc. These suspensions
were then banded in isopycnic gradients by centrifuging at 130,000 x g for 48 h. The
virus band was separated by drop collection from the bottom of the tubes. The CsCl salt
was removed from the purified virus by dialysis against PBS overnight at 4 oC. For
fluoresceination of the purified virus, a procedure similar to that reported by Freistadt
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and Eberle (44) was used. N-Hydroxysuccinimide (NHS)-Fluorescein (Pierce) was
used to directly label purified virus. This reagent was prepared and handled according
to the manufacturer’s directions. Purified BPV was sonicated to break up possible viral
aggregates. A quantity of virus in 0.5 ml of PBS, with a BPV hemagglutination titer of
10,000 HA units per 50 µl, was combined with 2.5 µl of NHS-Fluorescein reagent then
incubated in the dark at 4oC for 2 h. Following this reaction, the labeled virus was
dialysed against PBS overnight at 4oC in the dark against multiple changes of PBS until
no more color escaped the dialysis bag. The virus was tested by standard BPV
infectivity assays to assess for infectious virus both before and after labeling and it was
found that infectivity remained after labeling although diminished by nearly 2 logs. The
labeled virus was stored at 4oC in the dark until used. Immediately prior to use, the
fluoresceinated virus was centrifuged in a microfuge for 1 min to remove possible viral
aggregates. All immunofluorescense observations were done in the Nikon Eclipse
E600 epifluorescence microscope.
Effect of actin inhibitors on cells. Verification of the activity of drugs thought to inhibit
actin polymerization was performed by observing morphologic alterations in the actin
contained in cells exposed to Cyt D or Lat A. EBTr cells as well as BEK cells were
seeded in shell vials in standard growth medium. They were allowed to attach to the
round glass coverslips (12 mm diameter) for 24 h, then the medium was renewed with
either standard control growth medium or test medium containing 0.1 μM Cyt D or 0.05
μM Lat A. Incubation was allowed to proceed for 24 h, then the cultures were washed in
PBS and fixed in -800 C acetone. Staining for actin was performed by covering the
coverslips with mouse anti-actin (Chemicon MAB 1501), incubating for 30 min at 37 0 C,
then washing with PBS-Tween and distilled water. This step was followed by a 30 min
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incubation with goat anti-mouse-Texas red conjugate (Invitrogen T862), then washes
with PBS-Tween, and distilled water. The cultures were then mounted in antifade
mounting fluid containing buffered glycerin, p-phenylenediamine and DAPI. DAPI was
used to render color contrast to the cell nuclei and make them more visible.
Fluorescence microscopic observation was performed in the Nikon fluorescence
microscope using the Texas red-DAPI filter and photomicrographs were taken under the
40X objective lens.
Real-time PCR. Cells were treated with pharmacological agents 30 min prior to virus
infection. Infection (MOI=1.5 TCID50/cell) proceeded for 24 h at 37oC in the presence of
the pharmacological agents. The cells were detached by trypsinization and pelleted as
recommended in RNA extraction kit (RNeasy mini kit, Qiagen). Total RNA was
extracted using the RNA extraction kit method following the manufacturer’s instructions.
cDNA synthesis was performed with the reverse primer (mProm-IITM Reverse
Transcriptase, Promega). Primers for BPV DNA amplification were designed using
Primer-BLAST (Primer-Basic Local Alignment Search Tool) which uses Primer3 to
design PCR primers for user-selected database.). The forward and reverse primers are
shown in TABLE 3. The RPLPO (large ribosomal protein) gene was used as a control
gene to normalize DNA quantity between samples and experiments. Amplification and
real-time detection of PCR products were performed on the cDNA samples using the
Lightcycler 400 system (Roche Diagnostics, Rotkreuz, Switzerland) with SYBR Green
(Roche). The fluorescent dye SYBR Green binds to double-stranded DNA. At the end of
the extension step of every cycle, the fluorescence was measured. The cycle number at
which the fluorescence starts to increase is related to the initial number of target copies.
Cycling conditions consisted of a step at 95 oC for 10 min to activate the polymerase
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enzyme followed by 35 cycles with the following thermal profile: 94 oC and 15 s, 66oC
and 5 s, and 72oC and 30 s. For each quantitative PCR analysis, 4 μl of diluted DNA
was deposited in replicates for a 10 μl total reaction volume. The ratio of the amount of
amplified gene with the amount of RPLPO gene allowed us to compare accurately
expression of the genes of interest between different samples or treated and untreated
samples.

TABLE 3. Primer sets for viral RNA quantification by qPCR
Gene
NS

NP

VP

Protein function

Primer sequence (5I-3I)a

Orientation

Nonstructural early
protein, genome
replication

For

5I-CCA GTA CCA GGA AAC GGA GA-3I

Rev

5I-GTG TTG GCT GGA TGA AAC CT-3I

Early nonstructural
phosphoprotein

For

5I-CGA CTA GCC AGC AAA GGA AC-3I

Rev

5I-AAC AAT TCT CCC ACC CCT TC-3I

For

5I-CCA GTA CCA AAC GGA GA-3I

Rev

5I-GCG TTG ATG GTG TAT GC-3I

Capsid structural
protein

House keeping gene (large ribosomal protein) primers
For 5I-CCT TCC CAC TTG CTG AAA AG-3I
Rev 5I-GAC TCC TCC GAC TCC TCC TT-3I

_________________________________________________________________________________________________________

a primers in 5I to 3I orientation; (For) forward; (Rev) reverse.
RESULTS
Clathrin distribution in EBTr cells. To investigate the early steps of BPV infection, we
examined the distribution of clathrin on EBTr cells ensuring that these cells display a
rich array of this endocytosis machinery and to determine whether the anti-human
clathrin antibody reagent to be used in our studies would react with bovine clathrin.
Clathrin expression and its recycling between the plasma membrane and CCVs are
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crucial for membrane trafficking that is mediated by clathrin-associated vesicles.
Therefore, the distribution of clathrin on EBTr cells was investigated by
immunofluorescence microscopy with an anti-clathrin fluorescent antibody conjugated
with rhodamine. The results appeared to show that clathrin is abundantly distributed in
the plasma membrane, cytosol, and Golgi of EBTr cells (Fig. 1). Strong staining in the
perinuclear area is consistent with Golgi-associated clathrin. Furthermore, there was
strong cross reactivity evident between anti-human clathrin and clathrin of bovine origin.

FIG. 1. Distribution of clathrin on EBTr cells seen by immunofluorescence. Mouse antihuman clathrin reacted with bovine clathrin and was visualized using a rhodamineconjugated secondary antibody.
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BPV binding assays. The replication cycle of an animal virus begins with its binding to
a receptor expressed on the surface of a susceptible cell. Viruses simply use these cell
surface molecules for attachment. Some viruses bind to more than one receptor moiety,
and some are transferred to a secondary receptor before or during the penetration
process. It is known that BPV binds to the GPA molecule on erythrocytes through α2,3linked terminal neuraminic acid located on the O-linked oligosaccharides. GPA on
nucleated bovine cells binds to both 2,3-O-linked and 2,3-N-linked sialic acids. It is
not yet known whether BPV will bind to additional membrane associated molecules or if
it goes to a secondary receptor during penetration. Accordingly, dot blot assays were
used to examine BPV binding to sialic acids and other cell components fixed on the
nitrocellulose membranes. We unexpectedly observed that BPV would bind to clathrin.
In this assay purified and crude BPV antigen (positive controls), PBS (negative control),
GPA (as an additional positive control), and clathrin were fixed on the nitrocellulose
membrane. BPV was added on them. The membranes were then stained by anti-BPV
and the immunoenzyme complex for visualization of BPV binding to the membrane fixed
molecules. As seen on the dot blot membrane, we observed similar amounts of stain
intensity in wells with positive controls, GPA, and clathrin indicating BPV attachment to
GPA and, intrigingly, to clathrin as well (Fig. 2). Whatever function BPV binding to
clathrin may imply is at present unknown.
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FIG. 2. Binding of BPV to clathrin on a Dot Blot. Dot (A) consisted of the membrane
bound clathrin and virus. GPA, known to bind BPV, served as a positive control (B). A
negative control, PBS, was dotted (C). A second positive control consisting of crude
antigen cell lysate was included (D). Purified virus serving as a positive antibodyenzyme-chromogen control (E) was dotted directly on the nitrocellulose membrane.
Observation of BPV infected cells with electron microscopy. BPV infected EBTr
cells were scanned by TEM to observe endocytosis-associated structural components
at early points after infection. EBTr cells were suspended in PBS, infected with purified
virus stock previously produced on CsCl isopycnic gradients, and incubated at RT for 15
min. EBTr cells not infected with virus served as control. The BPV infected and
uninfected EBTr cells were then processed for electron microscopy analysis. Virus
particles were found externally at the thickened clathrin-associated regions of the
plasma membrane after 15 min of incubation at RT (Fig. 3B). These regions appear to
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be thickened as a result of clathrin recruitment at the cytoplasmic side of virus/receptor
complexes. The thickened regions of the plasma membrane in control cells were less
intense compared to the thickened regions of BPV infected EBTr cells (Fig. 3A, C, E). In
thickened clathrin-associated regions of the plasma membrane of BPV infected cells,
some areas invaginated to the cytosol forming pits (Fig. 3D), and the two ends of some
pits were closed making images of clathrin-coated invaginates ready to pinch off from
the plasma membrane (Fig. 4A). Images resembling CCV were also observed in the
thickened regions of the plasma membrane (Fig. 4B). Virus particles were found in
association with invaginate (Fig. 3D) and in vesicles resembling CCVs (Fig. 3F).
Scanning control cells with TEM did not reveal these endocytosis-associated structural
components.

28

A.

B.

C.

D.

E.

F.
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FIG. 3. Observation of control and infected cells using electron microscopy. (A)
uninfected cells showing an intercellular space. (B) Cells infected with BPV. Virus
particles in intercellular space (arrow). (C) View along the cell membrane of control
cells. Cells showing smooth membrane. (D) Virus-containing invaginate with
microscopically dense coat. (E) Intracellular compartments of uninfected cells. (F)
Vesicles containing virus and dense areas along the cell membrane consistent with
clathrin assembly.
A.

B.

FIG. 4. Apparent clathrin-associated structures in infected cells. (A) an invaginate with a
densely coated membrane (arrow).(B) cytosolic vesicle with a dense membrane.

It appears that these endocytosis-associated structural components in EBTr cells were
caused by BPV attachment, and BPV entry is mediated by endocytic vesicles. To
confirm these results, specific pharmacological drugs were used to test CME for BPV
entry into the host cell. At the same time, caveolae-associated receptor-mediated
endocytosis was investigated by the same approaches used to examine the clathrindependent pathway.
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BPV entry is dependent on clathrin. Virus binding to its specific receptor on the cell
surface triggers cell signaling pathways involved in virus penetration through the plasma
membrane. If virus entry is mediated by clathrin-dependent endocytosis, recruitment of
clathrin and its adaptor proteins leads to the formation of clathrin coated pits along the
plasma membrane regions where virus/receptor complexes are bound. Thus, we sought
to determine whether BPV uptake is affected by CHPZ treatment. Virus infectivity and
production assays were carried out with CHPZ. Potential toxic side effects of the drug
were determined by cell viability/toxicity tests. The inhibition of formation of clathrin
coated pits by CHPZ treatment strongly reduced virus infectivity from 29% to 70% (Fig.
5A) and titers of progeny viruses from 36% to 58% in a dose-dependent manner (Fig.
6A). These data indicate that BPV entry appears to be mediated by clathrin-dependent
pathway of endocytosis.
Because CME is a prominent mechanism for introducing cargo into cells, and
because it is dependent on endosomal acidification, blocking endosomal acidification
was undertaken and the results are shown in Figs. 5, 6, and 7. Inhibitors of endosomal
acidification are grouped into three classes based on their modes of action. The first
class is composed of the lysosomotropic weak bases, such as NH4Cl and CHLO. They
diffuse across membranes in a dose-dependent manner and rapidly become
protonated. This results in neutralization of the acidic environment of endocytic vesicles.
The second class of agents alters the endosomal pH by exchanging protons for
potassium and sodium. The third class of inhibitors consists of blockers of vacuolar H+ATPases such as Baf A1 that hinders transport H+ over membranes against an
electrochemical potential under ATP hydrolysis. Whether BPV uptake is affected by
acidification inhibitors was examined by virus infectivity and production in the presence
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FIG. 5. BPV infectivity in EBTr cells treated with the inhibitors of CME. EBTr cells were
treated with CHPZ (A), NH4Cl (B), CHLO (C), Baf A1 (D), or BFA (E) 30 min prior to the
virus infection. The drug concentrations were maintained during 48 hrs of virus infection.
Infectious centers were determined by IP staining. The results are expressed as
numbers of infectious centers in the treated cultures as a fraction (percent) of infectious
centers in untreated cultures (bar plots). Cell viability in drug treated cultures compared
to control cells without drug is shown by the data points. The data represent three
independent experiments performed with replicate cultures in triplicate per experiment.
Error bars represent standard errors of the means.

of NH4Cl, CHLO, or Baf A1. Virus infectivity depleted from 81% to 100% in NH4Cltreated cells (Fig. 5B). NH4Cl reduced virus production from 42% to 98% (Fig. 6B).
CHLO markedly inhibited virus infectivity (34-95%) and production (35-61%) after 48
hours and 72 hours infection, respectively (Fig. 5C and Fig. 6C). Vacuolar H+-ATPase
inactivation by Baf A1 reduced infectivity to 92% and production to 86% of BPV
infectivity and production in control cells (Fig. 5D and Fig. 6D). Collectively, these
results suggest that the low pH is required for BPV internalization and supported the
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evidence described above that an efficient BPV entry into EBTr cells is mediated by the
clathrin-mediated pathway of endocytosis. The inhibitory effect of the drugs was dosedependent. Working concentrations not toxic to EBTr cells were used to assess an
efficient BPV infection reliance on process blocked by the acidification inhibitors.
Confirmatory experiments were conducted by isolating viral RNAs from infected
control cells and infected cells in the presence of drugs. cDNA was constructed, then
DNA was amplified to determine whether the inhibitors of CME interfere with virus
infection in EBTr cells. qPCR results indicatet that NH4Cl (Fig. 7A) and CHPZ
treatments (Fig. 7B) inhibited virus replication in the host cell. Taken together, these the
the hypothesis data strengthened that the clathrin-mediated, pH-dependent pathway is
required for BPV uptake into EBTr cells, and it is essential for the downstream virus
replication events to occur.

FIG. 6.
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FIG. 6. Production of progeny virus in the presence of inhibitors of CME. Cells were
treated with CHPZ (A), NH4Cl (B), CHLO (C), or Baf A1 (D). The ratio of virus titers in
yields is plotted as percent of control (bars). The percent of viable cells was plotted
against at working concentrations of drugs (dot plots). Error bars represent standard
errors of the means.
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FIG. 7. Viral RNA synthesis quantification in cells treated with CME inhibitors. NH4Cl (2
mM) or CHPZ (5 μM) pretreated cells infected with virus for 24 h, and RNA was
extracted. Viral VP, NP, and NS genes’ expressions were measured by qPCR and as
described in Materials and Methods. Numbers >1 indicate gene expression is less than
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control cultures or cultures infected with virus in the absence of drugs. (A) NH4Cl or (B)
CHPZ compared to untreated infected cultures.

Cell viability assay. It was important to clarify whether the inhibitions seen in the
previous experiments were due to inhibition of the intracellular virus-associated
machinery or if it was due to death of the cells caused by drug cytotoxicity. Therefore,
the effects of the drugs at working concentrations on cell viability were tested by using
the MTT test for cytotoxicity. EBTr cells, were grown to confluency in 96-well plates,
treated with drugs and were incubated under the identical conditions at which the drugs
were used to analyze BPV entry and trafficking. The drug concentrations used in all
experimental cultures in this study did not significantly affect EBTr cell viability. This
implies that the inhibitory effect of drugs on virus infectivity, production, and transcription
was not due to drug toxicity. These results affirmed the selective inhibitory effects of the
drugs on virus replication events. Cell viability is plotted on Figs. 5 and 6 as well as
subsequent figures as indicated.
Trafficking of BPV through the early to late endocytic compartments. BPV
particles routing through the endosomal compartments was investigated. CCVs that
carry cargo or virus/receptor complexes lose the clathrin coat and mature to early
endosomes. Viruses of some families can escape into the cytoplasm from the early
endosomes or some traffic through late endosomes. Several groups of studying
parvoviruses have reported that endosomal acidification is crucial for parvovirus
infection, inducing capsid rearrangements followed by release of the virus into the
cytoplasm. Thus, we hypothesized that trafficking through endosomal compartments
might be essential for BPV entry. To identify BPV transit through endosomal
compartments, EBTr cells were treated with BFA, a blocker of endocytic traffic from
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early to late compartments. The drug inhibited BPV infectivity in a dose-dependent
manner. (Fig. 5E) These results indicated BPV transit through the early and late
endosomes, and it also supported results of the experiments run with the inhibitors of
endosomal acidification. BPV traffic through endosomal compartments and their acidic
environment is required for productive replication of BPV. The inhibitory effects on BPV
replication are noteworthy, and the concentrations we used did not have any direct
inhibitory effect on BPV particles (see next section) or on EBTr cell growth.
Test for virucidal activity of the drugs used in BPV entry studies. Possible direct
virucidal activity of the drugs on the virus strain we used in this study was tested by
treating virus stock with the highest concentration of drugs. Virus stock was incubated
for 30 min at RT with the highest doses of the drugs, and cell cultures were infected with
drug treated virus stock to test surviving virus. Infected monolayer cells were incubated
at 37oC and 5% CO2 for 2 days, and cells then processed for the detection of BPV
infected cells. The number of infected cells was scored in comparison to mock-treated
virus control cultures. For the most part we did not observe differences between the
control cultures and the cultures of drug treated virus (Fig. 8), although at these drug
concentrations CHLO and CHPZ slightly reduced virus titers. These results confirm that
the drugs we used in the study of BPV entry had no or only slight virucidal activities on
virus, and the depletion of BPV infectivity and virus production in EBTr cells we noted in
this study are not caused by direct inactivation of the BPV strain by the drugs.
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FIG. 8. Assessment of chemical inhibitors for direct virucidal activity. Virus was
exposed to the inhibitors at the highest drug concentration used in any of the studies.
Exposure was at RT for 30 min, then surviving virus assayed by standard techniques.
The control (1), infected with virus stock not treated with drugs, was normalized to 100%
survival. The survival rates of the other tests were compared to the control. The
inhibitors and concentrations were (2) NH4Cl, 4mM; (3) Baf A1, 200 nM; (4) CHLO, 0.01
mM; (5) CHPZ, 5 μM; (6) BFA, 0.05 μg/ml; (7) Nys, 1 μg/ml; (8) MBCD, 2.5 mM; (9)
Gen, 200 μM; and (10) PMA, 1000 nM.

Assessment of our techniques on a nonparvovirus control virus. To determine if
the techniques we used in this study could replicate results published for another virus,
we used an adenovirus model. Ad virus is a nonenveloped, DNA virus, which exploits
the clathrin-mediated pathway for cell penetration. Based on reports in the science
literature, we performed Ad virus infectivity assays in HeLa cells with inhibitors of
clathrin- (NH4Cl and CHPZ) and caveolae-mediated (Nys and PMA) pathways. The
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effect of these drugs on BPV replication was analyzed by infecting cells in the presence
of the drugs. HeLa cells growing in 24-well plates were treated with the drugs for 30 min
followed by Ad virus infection at 37oC and 5% CO2 in the presence of the drugs for 2
days. Infected cells were fixed with the FAA fixative and processed for the detection of
positive cells in relation to the number of virus antigen-positive cells in mock-treated
cells, and it is expressed as the percentage virus antigen-positive cells. Clathrindependent pathway inhibitors depleted Ad virus internalization 55% and 38% (NH4Cl
and CHPZ, respectively) (Fig. 9). Neither Nys nor PMA suppressed Ad virus entry into
HeLa cells. Ad virus infectivity was increased from 134% to 250% in cells treated with
Nys and PMA, an enhancement effect consistent with our observations on BPV
replication in Nys and PMA treated-EBTr cells.
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FIG. 9. Ad virus infectivity in HeLa cells in the presence of drugs. Ad virus is internalized
by CME. The effect of inhibitors of clathrin- (NH4Cl and CHPZ) and caveolin- associated
(Nys and PMA) pathways on Ad virus infectivity in HeLa cells was examined. HeLa cells
were pretreated with drugs and then infected with Ad virus. After 48 h infection, Ad virus
positive cells were scored in cultures treated with drugs and compared to Ad virus
positive cells in control cultures or untreated cultures.

Tracking virus entry using fluoresceinated virus. EBTr cells sheeted on 12mm
round coverslips in shell vials were infected with 10 µl of fluoresceinated virus per vial.
Immediately prior to infection, the virus was clarified by centrifugation for 1 min in a
microfuge to remove possible virus aggregates. At the end of the appropriate incubation
period, the cultures were washed in PBS, fixed in cold acetone (-80oC), air dried,
washed in a stream of PBS, and then distilled water. After co-staining for clathrin the
cultures were observed for fluorescence. Cultures fixed at 5 min post-infection, and 60
min and 90 min were observed. The virus (fluorescein label) could be distinguished
from clathrin (rhodamine label) (Fig. 10). At 5 min post-infection (A) the virus appeared
to be evenly distributed on the surface of the cells without aggregation and appeared to
be attached to viral receptors because it did not wash away during processing. The
clathrin, at this magnification, also appeared distributed about the cell and not collected
into endosomes. In contrast, by 60 min post-infection, the virus was clearly aggregated
(C) as was the clathrin (D). These co-localized structures appeared to result from
endosomal formation and contained large numbers of virus particles.
At 90 min post-infection (Fig. 11) cells observed at a higher magnification clearly
show large aggregates of virus associated with clathrin and appeared to result from
endosomal formation. The structures were commonly distributed throughout the
cytoplasm, even in long cytoplasmic processes. In some cells virus was observed to be
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somewhat concentrated in the perinuclear area of the cell. In merged
photomicrographs (not shown) the clathrin- and virus-associated structures exhibited
co-localization.
A.

B.

C.

D.

FIG.10. Interaction of fluoresceinated BPV particles with EBTr cells. The green images
show the virus particles and the red images show rhodamine-stained clathrin. At 5 min
post-infection (panels A and B) the virus particles were associated with the cytoplasmic
membrane primarily in a smooth, even pattern (A) showing the viral material started out
as non-aggregated virus particles. The clathrin was found distributed comparatively
evenly over the cells (B). By 60 min post-infection (panels C and D), the virus particles
were markedly aggregated (C) as shown by the granular distribution of virus. The
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cellular clathrin distribution (D) corresponded in a granular pattern with the virus
aggregates with co-localization of virus and clathrin. Magnification, 20X.
A.

B.

FIG. 11. Uptake of fluoresceinated BPV particles in EBTr cells at 90 min post-infection.
At this time point, the virus (panel A, green) appeared as large aggregates distributed
throughout the cytoplasm in association with endosomal clathrin (panel B). In some
cells, viral material collected around the perinuclear area. In merged images (not
shown), endosomal clathrin and viral protein aggregates co-localized in apparent
endosomes. Magnification, 40X.

BPV uptake by EBTr cells is independent of the caveolin pathway. Inhibitors of the
caveolin pathway also were used to test a role of caveolae-associated endocytosis for
BPV entry. To determine a role of caveolae pathway for BPV internalization into EBTr
cells, we analyzed the effects of a caveolin depletion agent (PMA), lipid raft blockers
(Nys and MBCD), and a tyrosine kinase blocker (Gen) with virus infectivity (Fig. 12) and
production assays (Fig. 13).
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The selective drugs allowed us to target interconnected organelles of caveolae
entry. None of these drugs affected BPV infectivity or production in EBTr cells (Fig. 12
and 13). We observed increases of BPV infectivity and virus production relative to
control with some drugs. Further investigations will be required to determine the precise
mechanisms of how some of these selective inhibitors enhance BPV replication.
However, enhancement is not unusual as seen in the adenovirus control experiments
(Fig. 9). All together, these results strongly indicated that BPV uptake by EBTr cells is
not by caveolin-associated, pH-independent pathway of endocytosis. Working
concentrations of the drugs used in the caveolae experiments were tested for toxicity by
the MTT test and for virucidal action. Viral RNA in Nys and PMA treated-EBTr cells was
measured by qPCR (Fig. 14). As expected, Nys did not inhibit virus transcription, but
interestingly, PMA decreased transcription of all three markers (NS, NP, and VP). What
role PMA plays in this blockage, whether relating to caveolin or another sensitive point
will require further analysis.
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FIG.12. BPV infectivity in EBTr cells treated with the inhibitors of caveolae-mediated
endocytosis. For details please refer to FIG. 5 legend. Cells were treated with Nys (A),
MBCD (B), PMA (C), or Gen (D). Error bars represent standard errors of the means.

FIG. 13.

A.
virus titer (% of control)

% of viable cells

150

100

120

75

90
50
60
25

30
0

0
0

0.1

0.25

0.5

1

Nystatin concentrations (μg/ml)

47

B.
virus titer (% of control)

% of viable cells

500

100

400

75

300
50
200
25

100
0

0
0

2.5

1

0.5

0.25

MBCD concentrations (mM)

C.
virus titer (% of control)

% of viable cells

600

100

500
75
400
300

50

200
25
100
0

0
0

10

100

500

1000

PMA concentrations (nM)

48

D.
virus titer (% of control)

% of viable cells

250

100

200

75

150
50
100
25

50
0

0
0

25

50

100

200

Genistein concentrations (μM)

FIG.13. Production of progeny virus in the presence of inhibitors of caveolae-mediated
endocytosis. For details please refer to FIG. 6 legend. Cells were treated with Nys (A),
MBCD (B), PMA (C), or Gen (D). Error bars represent standard errors of the means.
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FIG.14. Quantification of viral RNA in cells treated with inhibitors of the caveolae
pathway. For details please refer to FIG. 7 legend. (A) Nys (0.25 μg/ml) and (B) PMA
(1000 nM).
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The ubiquitin-proteasome system and BPV replication. It has been reported that a
variety of virus species is dramatically dependent on the ubiquitin-proteasome system to
establish productive infection through a diversity of distinct mechanisms. To determine
whether a relationship exists between BPV and the ubiquitin-proteasome system, EBTr
cells were treated with the antiproteasome drugs Lac and Epox prior to BPV infection.
The drugs were maintained in the cultures for the entire time of infection. Lac
suppresses the 26S proteasome related chymotrypsin- and trypsin-like activities. Epox
inactivates the chymotrypsin-like activity of the proteasome. The results demonstrated
that suppression of proteasome activity by selective inhibitors did not affect BPV
infectivity in the host cell (Fig. 15). Quantitative PCR results did show a significant
difference of viral transcripts in untreated and drug treated-EBTr cells (Fig. 16). Taken
together, these results suggest that BPV processing following clathrin-mediated pHdependent endocytosis does not require the proteasome-ubiquitin system. The drug
doses used in infectivity assays were not toxic to EBTr cells.
A.
# of infected cells (% of control)

% of viable cells

125

100

100

75

75
50
50
25

25
0

0
0

0.01

0.02

0.05

0.1

0.5

Epoxomicin concentrations (µM)

50

B.
# of infected cells (% of control)

% of viable cells

350

100

280

75

210
50
140
25

70
0

0
0

0.02

0.1

0.5

2

5

Lactacystin concentrations (µM)

FIG.15. BPV infectivity in proteasome enzyme inhibitors treated-EBTr cells. For details
refer to FIG. 5 legend. Cells were pretreated with Epox (A) and Lac (B), and the drugs
were maintained during the virus infection. Error bars represent standard errors of the
means.
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FIG.16. Quantification of viral RNA synthesis in the presence of proteasome activity
blockers. For details refer to FIG. 7 legend. Viral VP, NP and NS transcripts were
measured by qPCR in (A) Epox (0.05 μM) and (B) Lac (2 μM) treated-EBTr cells.

51

The role of actin in intracellular trafficking of BPV. Virus attachment to its receptor
molecule induces cell signaling on behalf of virus replication. Virus uptaken by the host
cell interacts with cell cytoskeletal structures and regulate them to reach to appropriate
sites of replication. Virus associated trafficking routes may involve microtubules, dynein
and kinesin motors, or actin filaments, and myosin motors. To characterize intracellular
trafficking of BPV, cells were treated with the specific blockers of cell cytoskeleton
synthesis or function and infected with virus. Viral protein expression and viral RNA
synthesis were detected in the drug treated and mock treated cells to identify which
component of the cell cytoskeleton may contribute to intracellular trafficking of BPV
particles. Growing evidence has suggested a tight interaction between the actin
network and CME. To analyze the role of actin filaments for BPV trafficking in the
cytosol, EBTr cells were treated with increasing noncytotoxic concentrations of actin
inhibitors, Cyt D, which inhibits actin polymerization, and Lat A, an inhibitor of actin
function. Following drug treatment cell cultures were infected with virus stock. An
efficient entry was scored as viral protein-expressing cells. Cyt D treatment resulted in a
reduction of BPV infectivity at 48 h post-infection in a dose-dependent manner (Fig.
17A). Lat A similarly depleted virus infectivity (Fig. 17B). The actin-myosin inhibitor, ML7, also inhibited infectivity (Fig. 17C).
The inhibitory effects of CME blockers strongly affirmed that CME is a functional
route of BPV entry into the host cell. Results shown in Fig. 17 indicate that actin
filaments participation for BPV trafficking and additionally confirm that CME is a
functional route of BPV uptake by EBTr cells. Further evidence was obtained by testing
all three of these inhibitors for inhibition of transcription. Viral RNA isolated from
untreated and drug treated cultures was detected by qPCR. Drugs active against actin
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markedly affected viral gene transcription (Fig.18). Overall, results suggest actin
transport is essential for BPV infectious cycle.
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FIG. 17. BPV infectivity in EBTr cells treated with actin blocking agents. For details refer
to FIG. 5 legend. Cells were treated with Cyt D (A), Lat A (B), and ML-7 (C).
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FIG. 18. Quantification of viral RNA synthesis in cells treated with drugs active against
actin transport. (A) Cyt D (0.1 μM), (B) Lat A (0.05 μM), and (C) ML-7 (5 μM). Details
given in FIG. 7 legend.

We speculated that because actin plays an important role in virus infection, it
might be possible to observe morphological changes in cells exposed to actin inhibitors.
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Accordingly, EBTr cells together with BEK cells (a cell strain derived from an embryonic
bovine kidney primary cell culture established in our laboratory) were exposed to media
containing Cyt D or Lat A. Fig. 19 shows the resulting morphological changes induced
upon exposure to these two drugs. Actin was stained with monoclonal anti-actin and
the fluorophore was Texas Red. The nuclei were stained by DAPI.
The EBTr cell morphology in control medium was typical with long, fibroblastic
cells (Fig. 19A). Actin filaments were clear, morphologically distinct, and appeared
highly organized. In the cells exposed to Cyt D (Fig. 19B) some actin filaments
remained, but most cells showed less clearly polymerized actin arrays and much more
amorphous actin. In the cells exposed to Lat A (Fig. 19C), there were very few actin
filaments to be seen in any of the cells. Most of the residual actin appeared in
amorphous masses. The cells exhibited extensive shrinkage that was consistent with
contraction of cell size and flattening due to loss of cytoskeletal structure.
BEK cells are large, cuboidal cells with an extensive actin cytoskeleton. In Fig.
19D BEK control cells can be compared to cells exposed to either Cyt D (Fig. 19E) or
Lat A (Fig. 19F). Cells with observably less actin found in filamentous forms and more
amorphous actin were seen in the drug treated cultures. Consistent with the Lat Atreated EBTr cells, the BEK cells exhibited cell shrinkage pulling away from each other
(Fig. 19F). Interestingly, the cell membranes appeared ruffled along the edges. These
results verify the effects of these two drugs on actin and are consistent with their activity
as inhibitors of actin polymerization and movement.
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FIG. 19. Immunofluorescence view of cells treated with actin inhibitors. A, B, and C
show the results of tests on EBTr cells and the BEK cells are shown in D, E, and F. (A)
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and (D) cells in the cell culture medium. (B) and (E) cells treated with Cyt D. (C) and (F)
cells treated with Lat A.

Myosin motors move cargo on actin filaments. Myosin function can be blocked
by standard drugs. In this study, we employed ML-7, a highly specific inhibitor of MLCK,
to examine the involvement of the myosin motor in BPV trafficking. Treatments by ML-7
strongly reduced BPV infectivity in EBTr cells (Fig. 17C). Moreover, the same drug was
active in reducing viral transcription (Fig. 18C). These results suggested the myosin
motor plays a functional role in BPV transport in the cytosol and affirmed results that
demonstrated the actin network interaction with intracellular BPV.
The microtubule network may be required for BPV infection. We also examined a
potential role of the microtubule network in the intracellular trafficking of BPV. Trafficking
through microtubules can be inhibited by specific drugs such as Noc. EBTr cells were
pretreated with Noc at increasing doses and infected with BPV for 48 h. Similarly EHNA
and Van were also tested. Noc did not exert any blocking effect on BPV infectivity when
the number of the drug treated viral protein expressing cells were compared to the
number of mock treated viral protein expressing cells (Fig. 20A). These results
suggested that the microtubule network may not be associated with the BPV entry route
into EBTr cells.
The microtubule-based dynein motor transports cargo, including virus or virus
containing vesicles, along microtubules towards the nucleus. A functional role of the
dynein motor in BPV infection was tested by using the inhibitors Van (a non-specific
dynein inhibitor) and EHNA (a dynein inhibitor). These drugs interfere with different
aspects of dynein motor function. BPV infectivity was not affected by treatments with
Van or EHNA as both drugs did not show any inhibitory effect on BPV protein synthesis.
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These results seemed to confirm that the microtubule network is not involved in BPV
trafficking.
Conflicting evidence was obtained when inhibition by these three drugs was
determined by blocking transcription as tested by qPCR. Noc, an inhibitor of
microtubule formation, showed strong interference with viral RNA synthesis (Fig. 21A).
Van did not block RNA synthesis (Fig. 21B), and EHNA produced mixed results with
blockage of NS and NP transcripts, but not VP (Fig. 21C). These discrepant results
need further study, but in the meantime our hypothesis is that microtubules and the
dynein motor traffick this virus to the nuclear membrane.
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FIG. 20. BPV infectivity in EBTr treated agents active against microtubules. Refer to the
FIG. 5 legend for details. Cells were treated with Noc (A), EHNA (B), and Van (C).
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FIG. 21. Quantification of viral RNA synthesis in cells treated with microtubule inhibitors.
(A) Noc (20μM), Van (20 μM) and (C) EHNA (0.5 μM) effects were tested against VP,
NP, and NS expressions. For details refer to FIG. 7 legend.

DISCUSSION
BPV is a common causative agent of cattle gastroenteritis. Serological surveys
indicate a high rate of infection in both dairy cattle and range cattle. Virus infection
usually involves multiple organ systems including the respiratory tract and internal
organs. It is presumed to transmit through the placental barrier infecting developing
fetuses. As with many other autonomous parvoviruses, BPV targets rapidly dividing
cells. Many studies on the replication cycles of these viruses have focused mainly on
the middle events of the replication cycle including genome replication and transcription.
Fewer studies have appeared on the early events of the replication cycle. Therefore,
understanding the early events of virus infection, i.e., exploring host factors involved in
entry and trafficking processes, will create a clearer global understanding of parvovirus
biology. Renewed attention is being given to the Bocaviruses since the identification of
the HBoV and BPV is the primary model for the study of Bocavirus infection. The aim of
60

this work was to investigate the early cellular events that lead to successful BPV
infection of the host cell.
We first assessed cellular and viral aspects involved in the most common entry
route of viruses, clathrin-dependent endocytosis. Our observations of an abundant
clathrin distribution on EBTr cells by immunofluorescence showed strong molecular
homology with human clathrin, and that EBTr cells would be a good model to examine
CME. Interestingly, we showed that the virus would bind to clathrin in a dot blot format,
suggesting a possible transition of bound virus from sialic acid receptors to clathrin (or
co-binding) in the transition from surface binding to coated pit, or from the coated pit to
the early endosome. However, if direct attachment of virus to clathrin has any role at all
in the replication cycle remains to be seen. Electron microscopy images of virus
infected cells were consistent with virus internalization mediated by a clathrinassociated pathway.
To confirm these observations we designed assays to block essential cellular
functions with specific pharmacological agents and analyzed the resulting effect on virus
replication. For a summary of the results, see TABLE 4. In this portion of the study, we
applied a variety of drugs to interrupt viral entry and trafficking at appropriate replication
compartments and at different intracellular steps. Moreover, blocking the proteosome
activity or various cytoskeletal structures and functions revealed previously unknown
information about mechanisms of intracellular transport to move the virus to the nucleus
for further processing.
Many studies have demonstrated that the clathrin-dependent endocytic pathway
is mainly required for uptake of members of the Parvoviridae family into cells (106, 128).
To verify BPV entry dependence on clathrin, we used CHPZ, a cationic amphiphilic drug
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that inhibits the formation of clathrin-coated pits at the plasma membrane. We found
that CHPZ strongly suppressed BPV infection in EBTr cells. Adenoviruses are reported
to enter cells also through the clathrin pathway (70). If, in our hands, CHPZ would block
Ad entry, such results would lend credence to the methods used in analyzing BPV
entry. Ad infection in HeLa cells was also depleted by CHPZ treatment supporting the
activity of CHPZ interference with BPV entry. The inhibition effect of CHPZ on Ad is
consistent with previous studies using CHPZ for investigation of baculovirus, FMDV,
HTV, HCV, MHV-2, PV, RV, SARS-CoV, and WNV entry via CME (13, 14, 21, 57, 59,
64, 74, 80, 90, 102). Since BPV entry into cells was strongly dependent on clathrin
assembly at the plasma membrane; we then definitively sought to determine the
requirement of endosomal acidification for BPV internalization.
Acidification of endosomes is known to be essential for viruses, which internalize
within CCVs. Studies of parvovirus entry reported that MVM, AAV, and CPV
internalization require endosomal acidification, and the endosomal acidic environment
may induce capsid conformational changes vital for viral release from endosomes to the
cytoplasm (4, 34, 76, 106). To define the role of pH in the BPV infection process, the
effects of NH4Cl, CHLO, and Baf A1, selective inhibitors of endosomal acidification,
were analyzed by functional assays. The weak bases, NH 4Cl and CHLO, diffuse across
the endosomal membrane and become protonated, causing the endosomes to become
less acidic. BPV infection was strongly sensitive to these weak bases in a dosedependent manner verifying acid pH dependency. A selective inhibitor of vacuolar H +ATPase, Baf A1 neutralizes the pH of intracellular vesicles via a different mechanism.
The results obtained with Baf A1 were similar to that obtained with weak bases. Thus,
altering the endosomal microenvironmental pH toward alkalinity demonstrated that a
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low-pH environment is necessary for BPV infection to progress to the next sequential
events in the cytoplasm.
Sensitivity to endosomal acidification raised a question regarding duration of the
virus within the endosome. That is, whether the virus particles are directly released from
the early endosomal compartment to the cytosol or are routed farther into the late
endocytic compartment. In an attempt to examine the virus endosomal traffic, we
analyzed the effect of a drug that disrupts the endosomal network, BFA. The results
indicated that BFA was active against BPV infection, suggesting that the virus particles
are not released from the early endosomes but instead traffic toward the late endosomal
compartment. Further studies on the location of capsid conformational changes
associated with endosomal acidification will help to clarify escape mechanisms and the
uncoating process.
The findings obtained by these virus replication studies were supported by
tracking the route of fluorescent-labeled BPV in cells. EBTr cells infected with
fluorescent labeled BPV (NHS-fluorescein) and stained with anti-clathrin antibodies
allowed visualization of virus at the cell surface and tracked it in the cytosol following
penetration of the plasma membrane. Photomicrographs showed that BPV co-localized
with clathrin concentrated areas at the cell membrane and endosomes in the cytosol.
The fluorescence micrographs by themselves are unconvincing, but taken together with
the biology of infection studies and the RNA transcript studies are consistent with the
trafficking pattern that has emerged.
One of the well known endocytic pathways is caveolae-dependent endocytosis.
The possible role of the caveolae-dependent pathway for BPV uptake was examined by
using inhibitor chemicals including Nys, MBCD, PMA, and Gen. These chemicals
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interrupt the caveolae-mediated pathway through different mechanisms. Functional
assays using these selective inhibitors did not affect BPV infection in EBTr cells: Nys,
PMA, MBCD, and the two lowest doses of Gen (25 μM and 50 μM) were not active
against virus production; Nys, PMA, and Gen did not impair virus infectivity; and MBCD
slightly depleted virus infectivity. This observation is in agreement with reports that
MBCD partially inhibited CME of transferrin receptor, EGFR, and SARS-CoV (57, 111).
The results strongly suggested that the caveolae-dependent endocytosis is not
responsible for BPV entry into EBTr cells. We observed much higher progeny virus
titers produced in cultures treated with Nys, PMA, MBCD, and the lowest dose of Gen;
MBCD gave slight suppression of virus infectivity.
Although there is a rich and extensive literature of reports using these same
chemical inhibitors for the same purposes that are reported in the current study. It is
essential to recognize the pleiotropic nature of these drugs and continually remain
cognizant of possible unexpected secondary effects. Our studies revealed marked
enhancement of virus infectivity and production in the presence of PMA. PMA was used
as a disrupter of caveolin-1 assembly at the plasma membrane to assess the caveolin
pathway as a possible entry route for BPV. PMA is a diester of phorbol and is a strong
tumor promoter. It is an activator of the signal transduction enzyme PKC. Thus, it
mimics the action of the natural diester diacylglycerol (DAG), which is also an activator
of PKC. PKC is actually a family of about 10 isozymes with the catalytic region being
highly conserved. PKCs, after activation, are translocated to the plasma membrane and
exhibit a multiplicity of functions such as modulating membrane structure events,
regulating transcription, and regulating cell growth. To date, we do not know the precise
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mechanism of PMA virus enhancement, but it may well link to cell growth regulation
stimulated by DAG-like activation of the PKC complex.
Virus escape from the endocytic organelles releases it into the cytosol. Once the
virus is released, the virus targets the nucleus by cellular factors that facilitate capsid
disassembly, exposure of the genome, and movement to an appropriate replication
compartment. To identify cellular factors interacting with virus particles immediately after
endosomal release, the cellular cytoskeleton and proteasome activity were investigated.
Again, tests detecting viral protein production were employed to determine whether the
proteasome or the cell cytoskeletal structures were involved in essential events in
movement of the virus to the nucleus. Further, inhibition of transcription was analyzed
as a measure of blocking movement of the viral genome to the nucleus in the presence
of specific inhibitors. Quantitative real-time PCR detecting NS, NP, and VP transcripts
provided valuable information. Our observations did not indicate that BPV interacts with
the proteasome. In an attempt to define the role of the multiple proteolytic functions of
the proteasome in BPV infection, we infected cells in the absence or presence of either
Epox or Lac. Epox, a chemical that selectively inhibits the chymotryptic activity of the
proteasome, did not affect virus infectivity except a slight enhancement with the lowest
dose of the drug. Moreover, Lac, which blocks chymotrypsin-like and trypsin-like
activities of the proteasome increased virus infectivity. These results indicate that the
ubiquitin-proteasome system may not provide an essential degradation process for
uncoating of this virus. However this point should be investigated further.
Finally, we tested viral intracellular trafficking dependence on the cytoskeleton
network. It has been reported that viruses that enter via receptor-mediated endocytosis
commonly require the cytoskeletal network to take the virus to a replication site (14, 15,
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17, 47, 48, 116, 118). Actin blocking agents, Cyt D, Lat A, and ML-7, reduced virus
infectivity. Further, to confirm the activity of these drugs on cell structures we tested the
effect of Cyt D and Lat A on EBTr cells by immunofluorescent microscopy.
Photomicrograph images showed evident changes in cell morphology, which
presumably was caused by actin disruption. The virus was also sensitive to
microfilament disrupting agents, Noc, EHNA, and Van as observed by RNA transcript
reduction but was not detected by reduction in infectivity. These differences were
unresolved but will be the subject of future research. The results of this aspect of our
studies suggested that BPV intracellular trafficking is dependent on actin and
microtubles.
In summary, our study defined early BPV entry events and its intracellular
trafficking. The results we obtained allowed us to map the main entry route of BPV and
trafficking in the cytosol. BPV, a Bocavirus and a member of the Parvoviridae family, is
up-taken by clathrin-coated pits, trafficks through the early- and late endosomal
compartments, and is dependent on the pH of intracellular vesicles. It is not yet known
whether capsid conformational change, which may allow endosomal escape, may occur
in the early or late endosome or whether the genome or an intact virion is released to
the cytosol. BPV infectivity or transcription failed to be mitigated by blocking
proteasomal function. Intracellullar trafficking is mediated by the actin and microtubule
networks. Future studies will refine our knowledge of the uncoating process and the
process this virus uses to translocate across the nuclear membrane to gain access to
the nuclear microenvironment.
The model displayed in FIG. 22, illustrates some of the known and proposed
events in the BPV replication cycle. Sialic acids are known receptors for BPV
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attachment to cells. The genomic structure is well documented with the entire
nucleotide sequence known and the locations of the three major open reading frames,
NS1, NP1 and VP (capsid), together with the putative NS2 ORF. The single
transcription promoter is located at map position P4. The mRNAs are separated from
large poly transcripts by a complex set of splices and are polyadenylated at internal and
terminal poly A signals. DNA synthesis is carried out by cell DNA polymerase along with
cell-specific auxiliary factors with genomic inverted terminal repeats functioning as
primers. Multimeric genome forms are generated with final encapsidation of primarily
negative sense monomeric genome copies. Egress has been reported to occur by cell
necrosis.
Our hypothesis for this project was that BPV is taken into the cell by an
endocytosis mechanism rather than direct penetration of the plasma membrane or by a
fusion mechanism. Moreover, we proposed that cytosolic trafficking events take the
virus to the nuclear membrane. Taken together, data accumulated in this study show
virus entry through the clathrin system. That blocking actin function inhibits virus
transcription, protein synthesis, and full virus replication, indicates the involvement of
actin in vesicular transport through the cytosolic milieu. Actin, together with myosin
motors, is known to perform essential functions for the cell. Myosin type I is involved in
membrane binding and endocytic vesicles. Myosin type V operates in vesicle transport,
and myosin type VI is involved in endocytosis. Thus, actin, together with one or all of
these myosin motor types, when inhibited could explain the observations we have seen
in this study. Inhibition of virus replication with blocking of microtubules may imply
movement of viral particles to the nuclear membrane in association with such
structures. That dynein may be the motor that moves the particles along micotubular
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filaments is a hypothesis at this time based on the observation that dynein is involved in
some models of retrograde movement to nuclei.
There are other hypothetical suggestions in the replication model. The function
of the PLA (phospholipase domain of VP) is unknown. The virus has to have some way
of escaping the late endosome with enough structural integrity to remain functional and
avoiding complete digestion as might be the case after lysosomal fusion. Some viruses
do this using the fusion domains of “F” proteins that fuse viral envelopes with
endosomal membranes. Because BPV is a nonenveloped virus it cannot use this
mechanism. Alternatively, it may provide a frontal attack on the endosomal membrane
by activation of phospholipase activity in a proton-rich environment. The freed, now
capsid-altered, particle is faced with finding the nuclear membrane. Binding to the
microtubule-dynein complex may solve this problem. These aspects of the replication
cycle, together with the mechanism of nuclear membrane penetration, are yet to be
elucidated.
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TABLE 4.Summary of results
Target

Mechanism

Inhibition of virus
Inf Prod RNA

1. Inhibitors of clathrin endocytosis
1.1 Chlorpromazine
prevents clathrin assembly at the cells surface.
+
+
+
1.2 Chloroquine
raises endosomal pH and blocks clathrin coated pit
+
+
formation.
1.3 Ammonium
increases endosomal pH and delays pinching of clathrin
+
+
+
chloride
coated pits from the cell membrane.
1.4 Bafilomycin A1
neutralizes endosomal acidification by inhibiting vacuolar +
+
ATP-ase.
2. Inhibitors of caveolin pathway
2.1 PMA
block caveolae formation at the cell surface.
+
2.2 Nystatin
depletes cholesterol in microdomains at the cell
-*
membrane.
2.3 MBCD
sequesters cholesterol in microdomains at the plasma
+** membrane.
2.4 Genistein
interferes with caveosome formation.
3. Inhibition of cytosolic trafficking
3.1 the early-to-late
endosome
+
3.1.1 Brefeldin A
interferes with transition from the-early-to-late endosome
3.2 Proteasome
3.2.1 Epoxomicin
inactivates the chymotrypsin-like activity of the
proteasome.
3.2.2 Lactacystin
active against the chymotrypsin- and trypsin-like
activities of proteasome.
3.3 Actin
3.3.1 Cytochalasin D
blocks actin polymerization.
+
+
3.3.2 Latrunculin A
binds to actin monomers delaying transport via actin.
+
+
3.3.3 ML-7
interferes with actin transport blocking phosphorylation
+
+
of MLC.
3.4 Microtubule
3.4.1 Nocodazole
inhibits microtubule formation
+
3.4.2 Vanadate
dimishes microtubule transport disrupting the dynein
motor.
3.4.3 EHNA
inactivates the microtubule-based dynein motor through
+***
ATPase.
+ inhibition; – no inhibition; nystatin* NS gene was enhanced; MBCD** (see 57, 111);
EHNA***VP gene enhancement; NP and NS genes inhibition; Inf (infectivity); Prod (productivity);
RNA (qPCR)

69

Endocytosis
Dynamin

Attachment
Clathrin

AP2 complex

BPV

Coated
vesicle

Clathrin recycling

Vesicle transport:
Actin, myosin V
Sialic
Acid
-2,3)

H+
Late endosome
pH 5.0
(PLA revealed)

Early endosome

Endosomal escape

5’

Nucleus

Nuclear trafficking
Microtubules
Dynein motors?

Protein
synthesis

DNA synthesis

Transcription:
RNA polymerase II

Structural
proteins

ssDNA

Assembly
Egress

FIG. 22. A proposed model for BPV replication. Following attachment to alpha-2,3sialic acid (O- or N-linked) the virus is endocytosed through the clathrin acid-mediated
system. The actin-myosin V complex is responsible for vesicular transport. The
transition from early to late endosome is accompanied by protonation which reveals the
virus phospholipase moiety (PLA) which controls particle escape from the endosome.
Trafficking from this cytosolic compartment to the nuclear membrane is controlled by
polar microtubules and driven by the dynein motor. Penetration of the nuclear
membrane allows for some capsid protein to remain attached to the 5’ end of the
ssDNA genome. DNA synthesis is performed by cell DNA polymerase forming a
double stranded intermediate which is transcribed to the mRNAs that are formed from
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a single promoter and a splicing array. The structural proteins, encoded in the CAP
ORF, assemble to form empty procapsids with subsequent packaging of negative
sense genome copies. Egress occurs by cell necrosis.
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